ReviewFood science & nutrition2023
A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action.
Review in Food science & nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Ellagic Acid and Metformin: In Vitro Synergy and Enhanced Cisplatin Efficacy In Vivo in Resistant Breast Cancer.Nutrients · 2026Article
- Effects of pomegranate seed extract and ellagic acid on miR-16-5p and miR-34a-5p expression, cell cycle, and apoptosis in MCF-7 cells.Research in pharmaceutical sciences · 2026Article
- Phytochemical, in silico, and in vitro studies of wheatgrass (Triticum aestivum L.) juice powder.Scientific reports · 2026Article
- Metabolites extracted from browntop millet (Urochloa ramosa (L.) T.Q. Nguyen) mitigated the proliferation of breast- and colorectal carcinoma cellsFrontiers in pharmacology · 2026Article
- Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Nerolidol-loaded beta-cyclodextrin nanoparticles modulate Nrf-2/Keap1/NF-κB signaling to inhibit DMBA-induced mammary carcinogenesis in Sprague-Dawley rats.Medical oncology (Northwood, London, England) · 2025Article
- Enhanced Killing of Colon Cancer Cells by Mesoporous Silica Nanoparticles Loaded with Ellagic Acid.Nanomaterials (Basel, Switzerland) · 2025Article
- Phytochemicals in Breast Cancer Prevention and Therapy: Mechanisms, Efficacy, and Future Prospects.Current issues in molecular biology · 2025Review
- Nobiletin reduces 5-FU-induced lung injury with antioxidative, anti-inflammatory and anti-apoptotic activities.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Unraveling Nature's Pharmacy: Transforming Medicinal Plants into Modern Therapeutic Agents.Pharmaceutics · 2025Review
- Comprehensive pharmacokinetic profiling and molecular docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer.Scientific reports · 2025Article
- High-Resolution LC-MS Simultaneous Quantification of Forty-Six Compounds fromMolecules (Basel, Switzerland) · 2025Article
- Utilizing Indigenous Flora in East Africa for Breast Cancer Treatment: An Overview.Anti-cancer agents in medicinal chemistry · 2025Review
- Ellagic Acid and Pomegranate (Aquaculture nutrition · 2025Article
- Article
- Discovery of a Novel Co-crystal of Chrysin and Oroxylin A with Anticancer Properties from Leaves ofAnti-cancer agents in medicinal chemistry · 2025Article
- Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Double-Edged Sword Effect of Diet and Nutrition on Carcinogenic Molecular Pathways in Breast Cancer.International journal of molecular sciences · 2024Review
- Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy.Biologics : targets & therapy · 2024Review
- A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action.Food science & nutrition · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, breast cancer (BC) is the leading cause of cancer-related deaths in women. Hence, developing a therapeutic plan to overcome the disease is crucial. Numerous factors such as endogenous hormones and environmental factors may play a role in the pathophysiology of BC. Regarding the multi-modality treatment of BC, natural compounds like ellagic acid (EA) received has received increased interest in antitumor efficacy with lower adverse effects. Based on the results of this comprehensive review, EA has multiple effects on BC cells including (1) suppresses the growth of BC cells by arresting the cell cycle in the G0/G1 phase, (2) suppresses migration, invasion, and metastatic, (3) stimulates apoptosis in MCF-7 cells via TGF-β/Smad3 signaling axis, (4) inhibits CDK6 that is important in cell cycle regulation, (5) binds to ACTN4 and induces its degradation via the ubiquitin-proteasome pathway, inducing decreased cell motility and invasion in BC cells, (6) inhibits the PI3K/AKT pathway, and (7) inhibits angiogenesis-associated activities including proliferation (reduces VEGFR-2 tyrosine kinase activity). In conclusion, EA exhibits anticancer activity through various molecular mechanisms that influence key cellular processes like apoptosis, cell cycle, angiogenesis, and metastasis in BC. However, further researches are essential to fully elucidate its molecular targets and implications for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.